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(T-NHL), whether in newly diagnosed or relapsed settings, is a
formidable clinical challenge. This heterogeneous group of
malignancieshas both innate and acquired chemoresistance to
standard regimens and, with a few notable exceptions, most
subtypes have poor long-term outcomes. The current initial
treatment paradigm for nodal T-NHL is, unfortunately, based
onpatients included in aggressive B cell lymphoma trials in the
1990s. Thus, standard-dose, anthracycline-based regimens,
such as CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisone) are the default standard of care for T-NHL, despite
long-termsurvival ratesofonly20%to40%andas lowas10%for
those with high-risk features [1,2]. Furthermore, recent
population-based data suggest that median overall survival
(OS) after relapse is less than 6 months, particularly if he-
matopoietic stem cell transplantation (HCT) is not performed
[3]. A number of novel agents are now approved in T cell lym-
phomas that may change the future treatment landscape, but
fornow,HCTretainsan important role in themanagementofT-
NHL. However, both the timing of HCT and the best modality,
autologous versus allogeneic, are controversial topics.
In this issueofBiologyof BloodandMarrowTransplantation,
Beitinjanesh et al. report on a single-institution retrospective
analysis of patients with nodal T-NHL undergoing HCT on
institutional transplantation protocols at MD Anderson Can-
cer Center [4]. Although they included patients spanning
almost 2 decades, the majority of transplantations were per-
formed after the year 2000, and they excluded anaplastic
lymphoma kinaseepositive anaplastic large cell lymphoma
(ALCL) patients, which is the only favorable subtype of nodalDOI of original article: http://dx.doi.org/10.1016/j.bbmt.2015.01.013.
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(PTCL)enot otherwise speciﬁed, angioimmunoblastic T cell
lymphoma (AITL), or anaplastic lymphoma kinase (ALK)e
negativeALCL, 58 underwentHCTas part of front-line therapy
(47 autologous HCT [autoHCT] and 11 allogeneic HCT
[alloHCT]) and 76 patients received HCT (41 autoHCT and 35
alloHCT) in the relapsed setting.Overall, themain conclusions
of their analysis are consistentwithother reports that indicate
that HCT is most effective when performed as part of initial
therapy, chemosensitivity is the most important predictor of
outcome, and, reﬂecting greater nonrelapse mortality,
alloHCT does not have superior outcomes compared with
autoHCT. Although this report conﬁrms published data, it also
raises a number of important considerations regarding the
timing and type of HCT utilized.
Conﬁrming a growing number of retrospective and pro-
spective publications [5], the current report ﬁnds that con-
solidative autoHCT in the front-line setting has promising
outcomes. Speciﬁcally, with a median follow-up of 35 months,
the 4-year progression-free (PFS) and OS are 56% and 75%,
respectively. Forpatients inﬁrst complete remission, the4-year
PFS and OSwere 64% and 84%, respectively. Although these are
impressive numbers, this study shares the caveat with many
others: patientswho are unable to undergo transplantation are
not included. For example, the prospective Nordic NLG-T-01
trial of dose-dense cyclophosphamide, doxorubicin, vincris-
tine, etoposide, prednisone (CHOEP) plus autoHCT consolida-
tion found that one third of patients were unable to undergo
planned transplantation because of progression or other
treatment failure [6]; similarly, a prospective German trial re-
ported thatonly66%ofpatients initiallyenrolled couldundergo
planned autoHCT [7]. The current paper by Beitinjanesh et al.,
by design, only included patients referred to a tertiary care
center and able to undergo HCT; thus, the denominator of po-
tential patients unable to be considered for HCT is unknown,
and these excellent outcomesmust be tempered as they reﬂect
a relatively selected patient population.
The most important conﬁrmatory ﬁndings in this paper
are the favorable signiﬁcance of chemosensitive disease and
that earlier transplantation (of either modality) may be very
helpful in improving outcomes. These are similar to the
major conclusions in a Center for International Blood and
Marrow Transplant Research (CIBMTR) analysis of autoHCT
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disease-based differences in autoHCT and alloHCT recipients,
a unifying observation was that transplantation was often
offered late in the disease course, with 50% of alloHCT and
30% of autoHCT patients receiving more than 2 prior treat-
ment regimens. This translated to worse outcomes: patients
receiving more than 2 lines of therapy had a 3-fold increased
risk of relapse, 5-fold increased risk of overall mortality, and
7-fold increased risk of nonrelapse mortality. Similarly, pa-
tients with chemotherapy-resistant disease had a 2-fold
increased risk of relapse, treatment failure, and overall
mortality. The current study similarly found that patients
with primary induction failure, an incomplete response to
induction treatment (ie, partial response), or multiple lines
of treatment were associated with inferior outcomes. The
main conclusion of the authors is that transplantation is
most beneﬁcial when offered as part of ﬁrst- or second-line
therapy, particularly if there is chemosensitivity.
An additional conﬁrmatory ﬁnding is the description of
graft-versus-lymphoma (GVL). A potent GVL effect in T-NHL
has been previously reported [9-12]. At least 1 group has
shown inferior outcomes and increased relapse after non-
myeloablative regimens, suggesting that it is the combined
impact of the preparative regimen as well as allogeneic stem
cell source that affects outcomes. The current paper supports
a GVL effect via 4 patients responding to donor lymphocyte
infusion and 4 of 8 patients who relapsed after autoHCT
enjoying long-term survival after a salvage alloHCT. Although
there are controversies over the relative value of myeloa-
blative versus reduced-intensity regimens, the current paper
found no statistically signiﬁcant differences based on
regimen intensity.
Two highly controversial topics elicited by the current
manuscript are whether or not alloHCT should be considered
as ﬁrst-line treatment in any T-NHL patient, and second,
whether or not autoHCT can be successful in the relapsed
setting. When should alloHCT be considered as a front-line
consolidation? The current study does not deﬁne why pa-
tients were chosen for auto versus alloHCT modality, but
others have shown that high International Prognostic Index
(IPI) and non-ALCL histologies do not beneﬁt as much from
consolidative autoHCT [6,7]. For example, in the Nordic trial,
5-year OS was over 70% for ALCL versus approximately 50%
for PTCL-not otherwise speciﬁed and AITL. Similarly, a high
prognostic index for peripheral T cell lymphoma, unspeciﬁed
(PTCL-U) score reduces long-term outcomes from approxi-
mately 50% to less than 20% [7]. Accordingly, a recent pro-
spective trial of consolidative alloHCT in initial management
enrolled 23 patients; in contrast to the prognostic factors
identiﬁed in autoHCT settings, neither the histology nor the
prognostic index for PTCL-U affected outcomes and 16 of 23
patients remain in a continuous remission with a median
follow-up of 40 months [11]. Although these are small
numbers, the combined ﬁnding that autoHCT is not as
effective in high-risk patients and that alloHCT is feasible is
provocative and suggests that alloHCT as ﬁrst-line therapy
may be reasonable for some patients. Only 11 patients un-
derwent alloHCT as front-line consolidation in the current
report. Although not statistically signiﬁcant because of the
small number of patients, patients undergoing alloHCT as
part of initial treatment were numericallymore likely to have
bone marrow involvement (27% versus 4%), receive more
lines of treatment before HCT (median 2 versus 1 prior
regimen), and have primary induction failure (45% versus
19%). Despite these adverse features, outcomes are similar tothose for patients who received autoHCT consolidation with
4-year PFS and OS of 34% and 54%, respectively.
Thesecondcontroversial issueraisedby thecurrentpaper is
the role of autoHCT in relapsed settings. To date, there are no
prospective data evaluating the feasibility and efﬁcacy of
autoHCT in relapsed T-NHL. Most reports are retrospective,
small, and from a single institution, and they collectively show
poor outcomes, particularly when compared with front-line
datasets. For example, a Stanford analysis found only 10%
long-term disease control after autoHCT at relapse [13]; simi-
larly, an Italian study of 40 patients found themedian PFS after
autoHCT at relapse to be only 6 months [14]. In contrast, reg-
istry trials show more optimistic ﬁndings. The CIBMTR evalu-
ated115patientsundergoingautoHCT; afterexcludingpatients
who underwent transplantation in ﬁrst remission, the 3-year
PFS and OS were 41% and 53%, respectively [8]. However, pa-
tients undergoing autoHCT at relapse in the CIBMTR analysis
were also more likely to have chemosensitive disease, harbor
ALCL histology, and have fewer lines of therapy.
The current report includes 41 patients undergoing
autoHCT at relapse and is 1 of the larger single-institution co-
horts to be evaluated. Patients undergoing autoHCT in second
or third complete remission had a 4-year OS of 59%; the ma-
jorityof patients hadALCLorPTCLhistology. Although afﬂicted
by the same caveats discussed in the front-line setting, these
numbers suggest that there are somepatientswhowill beneﬁt
from autoHCT, even if this is performed in the relapsed setting.
Finally, although the title of the current report suggests a
comparative intent of autoHCT versus alloHCT, it is difﬁcult
to draw conclusions with relatively small patient numbers in
each group and the comparative analysis should be viewed
with caution. Most other datasets have not been able to
compare autoHCT and alloHCT because of a recurring theme
that patients selected for alloHCT tend to have more adverse
features. For example, the initial intent of the aforemen-
tioned CIBMTR study was to compare autoHCT and alloHCT
outcomes, but there were substantially differing baseline
characteristics by treatmentmodality and a true comparative
analysis could not be performed. Patients undergoing
autoHCT were more likely to be in ﬁrst complete remission,
have chemotherapy-sensitive disease, have ALCL subtype,
and have 2 or fewer lines of prior therapy.
Overall, the MD Anderson Cancer Center experience
highlights the outcomes of T-NHL patients undergoing HCT.
The retrospective nature and multiple caveats mentioned
above challenge the ability to make strong and deﬁnitive
conclusions; nevertheless, it is clear that there is a subset of
patients with T-NHL who achieve long-term disease control
and survival with transplantation modalities. Prospective
trials focused on identifying the best candidates, increasing
the number of patients eligible for transplantation strategies,
and incorporating more rational agents into the treatment
paradigm earlier in the disease course are all badly needed.
For now, this report supports accumulating literature that
HCT remains an important tool in management of T-NHL via
both autologous and allogeneic modalities.
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